Retroviral Restriction Factor APOBEC3G Delays the Initiation of DNA Synthesis by HIV-1 Reverse Transcriptase

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Adolph, Madison B ^a   Webb, Jonathon ^a   Chelico, Linda ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; RNA DIRECTED DNA POLYMERASE; SINGLE STRANDED DNA;

ARTICLE; BINDING SITE; CONTROLLED STUDY; DEAMINATION; DNA SYNTHESIS; ENZYME INHIBITION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE GENE; IN VITRO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN POLYMERIZATION; PROTEIN PROTEIN INTERACTION; REVERSE TRANSCRIPTION; VIRION; VIRUS GENE;

ANIMALS; BINDING SITES; CYTIDINE DEAMINASE; DNA REPLICATION; DNA, VIRAL; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; KINETICS; POLYMERIZATION; PROTEIN BINDING; SF9 CELLS; SPODOPTERA;

EID: 84878155868     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064196     Document Type: Article

References (53)

1. Sheehy AM, Gaddis NC, Choi JD, Malim MH, (2002) Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418: 646-650.
2. Sheehy AM, Gaddis NC, Malim MH, (2003) The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med 9: 1404-1407.
3. Yu X, Yu Y, Liu B, Luo K, Kong W, et al. (2003) Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302: 1056-1060.
4. Marin M, Rose KM, Kozak SL, Kabat D, (2003) HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med 9: 1398-1403.
5. Kao S, Khan MA, Miyagi E, Plishka R, Buckler-White A, et al. (2003) The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. J Virol 77: 11398-11407.
6. Stopak K, de Noronha C, Yonemoto W, Greene WC, (2003) HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell 12: 591-601.
7. Simon JH, Gaddis NC, Fouchier RA, Malim MH, (1998) Evidence for a newly discovered cellular anti-HIV-1 phenotype. Nat Med 4: 1397-1400.
8. Suspene R, Sommer P, Henry M, Ferris S, Guetard D, et al. (2004) APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase. Nucleic Acids Res 32: 2421-2429.
9. Yu Q, Konig R, Pillai S, Chiles K, Kearney M, et al. (2004) Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat Struct Mol Biol 11: 435-442.
10. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, et al. (2003) DNA deamination mediates innate immunity to retroviral infection. Cell 113: 803-809.
11. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, et al. (2003) Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424: 99-103.
12. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, et al. (2003) The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424: 94-98.
13. Navarro F, Bollman B, Chen H, Konig R, Yu Q, et al. (2005) Complementary function of the two catalytic domains of APOBEC3G. Virology 333: 374-386.
14. Jarmuz A, Chester A, Bayliss J, Gisbourne J, Dunham I, et al. (2002) An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 79: 285-296.
15. Chelico L, Sacho EJ, Erie DA, Goodman MF, (2008) A model for oligomeric regulation of APOBEC3G cytosine deaminase-dependent restriction of HIV. J Biol Chem 283: 13780-13791.
16. Chelico L, Prochnow C, Erie DA, Chen XS, Goodman MF, (2010) Structural model for deoxycytidine deamination mechanisms of the HIV-1 inactivation enzyme APOBEC3G. J Biol Chem 285: 16195-16205.
17. Wedekind JE, Gillilan R, Janda A, Krucinska J, Salter JD, et al. (2006) Nanostructures of APOBEC3G support a hierarchical assembly model of high molecular mass ribonucleoprotein particles from dimeric subunits. J Biol Chem 281: 38122-38126.
18. Bennett RP, Salter JD, Liu X, Wedekind JE, Smith HC, (2008) APOBEC3G subunits self-associate via the C-terminal deaminase domain. J Biol Chem 283: 33329-33336.
19. McDougall WM, Okany C, Smith HC, (2011) Deaminase activity on single-stranded DNA (ssDNA) occurs in vitro when APOBEC3G cytidine deaminase forms homotetramers and higher-order complexes. J Biol Chem 286: 30655-30661.
20. Huthoff H, Autore F, Gallois-Montbrun S, Fraternali F, Malim MH, (2009) RNA-dependent oligomerization of APOBEC3G is required for restriction of HIV-1. PLoS Pathog 5: e1000330.
21. Chelico L, Pham P, Calabrese P, Goodman MF, (2006) APOBEC3G DNA deaminase acts processively 3′→5′ on single-stranded DNA. Nat Struct Mol Biol 13: 392-399.
22. Feng Y, Chelico L, (2011) Intensity of deoxycytidine deamination of HIV-1 proviral DNA by the retroviral restriction factor APOBEC3G is mediated by the non-catalytic domain. J Biol Chem.
23. Rein A, Henderson LE, Levin JG, (1998) Nucleic-acid-chaperone activity of retroviral nucleocapsid proteins: significance for viral replication. Trends Biochem Sci 23: 297-301.
24. Coffin JM, Hughes SH, Varmus HE (1997) Retroviruses. Plainview (NY): Cold Spring Harbor Laboratory Press.
25. Rausch JW, Le Grice SF, (2004) 'Binding, bending and bonding': polypurine tract-primed initiation of plus-strand DNA synthesis in human immunodeficiency virus. Int J Biochem Cell Biol 36: 1752-1766.
26. Iwatani Y, Chan DS, Wang F, Maynard KS, Sugiura W, et al. (2007) Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Res 35: 7096-7108.
27. Gillick K, Pollpeter D, Phalora P, Kim EY, Wolinsky SM, et al. (2013) Suppression of HIV-1 infection by APOBEC3 proteins in primary human CD4(+) T cells is associated with inhibition of processive reverse transcription as well as excessive cytidine deamination. J Virol 87: 1508-1517.
28. Bishop KN, Verma M, Kim EY, Wolinsky SM, Malim MH, (2008) APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog 4: e1000231.
29. Wang X, Ao Z, Chen L, Kobinger G, Peng J, et al. (2012) The cellular antiviral protein APOBEC3G interacts with HIV-1 reverse transcriptase and inhibits its function during viral replication. J Virol 86: 3777-3786.
30. Guo F, Cen S, Niu M, Saadatmand J, Kleiman L, (2006) Inhibition of formula-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication. J Virol 80: 11710-11722.
31. Guo F, Cen S, Niu M, Yang Y, Gorelick RJ, et al. (2007) The interaction of APOBEC3G with human immunodeficiency virus type 1 nucleocapsid inhibits tRNA3Lys annealing to viral RNA. J Virol 81: 11322-11331.
32. Li XY, Guo F, Zhang L, Kleiman L, Cen S, (2007) APOBEC3G inhibits DNA strand transfer during HIV-1 reverse transcription. J Biol Chem 282: 32065-32074.
33. Mbisa JL, Barr R, Thomas JA, Vandegraaff N, Dorweiler IJ, et al. (2007) Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J Virol 81: 7099-7110.
34. Miyagi E, Opi S, Takeuchi H, Khan M, Goila-Gaur R, et al. (2007) Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1. J Virol 81: 13346-13353.
35. Schumacher AJ, Hache G, Macduff DA, Brown WL, Harris RS, (2008) The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction. J Virol 82: 2652-2660.
36. Gao F, Robertson DL, Morrison SG, Hui H, Craig S, et al. (1996) The heterosexual human immunodeficiency virus type 1 epidemic in Thailand is caused by an intersubtype (A/E) recombinant of African origin. J Virol 70: 7013-7029.
37. Le Grice SF, Gruninger-Leitch F, (1990) Rapid purification of homodimer and heterodimer HIV-1 reverse transcriptase by metal chelate affinity chromatography. Eur J Biochem 187: 307-314.
38. Briggs JA, Simon MN, Gross I, Krausslich HG, Fuller SD, et al. (2004) The stoichiometry of Gag protein in HIV-1. Nat Struct Mol Biol 11: 672-675.
39. Xu H, Chertova E, Chen J, Ott DE, Roser JD, et al. (2007) Stoichiometry of the antiviral protein APOBEC3G in HIV-1 virions. Virology 360: 247-256.
40. Zhu P, Chertova E, Bess J Jr, Lifson JD, Arthur LO, et al. (2003) Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions. Proc Natl Acad Sci U S A 100: 15812-15817.
41. Reddy MK, Weitzel SE, von Hippel PH, (1992) Processive proofreading is intrinsic to T4 DNA polymerase. J Biol Chem 267: 14157-14166.
42. Lakowicz J (1983) Principles of Fluorescence Spectroscopy. New York: Plenum Press.
43. Liu S, Harada BT, Miller JT, Le Grice SF, Zhuang X, (2010) Initiation complex dynamics direct the transitions between distinct phases of early HIV reverse transcription. Nat Struct Mol Biol 17: 1453-1460.
44. Iwatani Y, Takeuchi H, Strebel K, Levin JG, (2006) Biochemical activities of highly purified, catalytically active human APOBEC3G: correlation with antiviral effect. J Virol 80: 5992-6002.
45. Isel C, Lanchy JM, Le Grice SF, Ehresmann C, Ehresmann B, et al. (1996) Specific initiation and switch to elongation of human immunodeficiency virus type 1 reverse transcription require the post-transcriptional modifications of primer tRNA3Lys. EMBO J 15: 917-924.
46. Lanchy JM, Ehresmann C, Le Grice SF, Ehresmann B, Marquet R, (1996) Binding and kinetic properties of HIV-1 reverse transcriptase markedly differ during initiation and elongation of reverse transcription. EMBO J 15: 7178-7187.
47. Thrall SH, Krebs R, Wohrl BM, Cellai L, Goody RS, et al. (1998) Pre-steady-state kinetic characterization of RNA-primed initiation of transcription by HIV-1 reverse transcriptase and analysis of the transition to a processive DNA-primed polymerization mode. Biochemistry 37: 13349-13358.
48. Vaccaro JA, Singh HA, Anderson KS, (1999) Initiation of minus-strand DNA synthesis by human immunodeficiency virus type 1 reverse transcriptase. Biochemistry 38: 15978-15985.
49. Creighton S, Bloom LB, Goodman MF, (1995) Gel fidelity assay measuring nucleotide misinsertion, exonucleolytic proofreading, and lesion bypass efficiencies. Methods Enzymol 262: 232-256.
50. Fygenson DK, Goodman MF, (1997) Appendix. Gel kinetic analysis of polymerase fidelity in the presence of multiple enzyme DNA encounters. J Biol Chem 272: 27931-27935.
51. Liu S, Abbondanzieri EA, Rausch JW, Le Grice SF, Zhuang X, (2008) Slide into action: dynamic shuttling of HIV reverse transcriptase on nucleic acid substrates. Science 322: 1092-1097.
52. Suspene R, Rusniok C, Vartanian JP, Wain-Hobson S, (2006) Twin gradients in APOBEC3 edited HIV-1 DNA reflect the dynamics of lentiviral replication. Nucleic Acids Res 34: 4677-4684.
53. Wurtzer S, Goubard A, Mammano F, Saragosti S, Lecossier D, et al. (2006) Functional central polypurine tract provides downstream protection of the human immunodeficiency virus type 1 genome from editing by APOBEC3G and APOBEC3B. J Virol 80: 3679-3683.